Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)

v3.24.2.u1
Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Nov. 14, 2022
shares
Nov. 01, 2022
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2024
USD ($)
item
shares
Jun. 30, 2023
USD ($)
item
shares
Jun. 30, 2022
USD ($)
item
Oct. 28, 2022
shares
Oct. 27, 2022
shares
Proceeds from sale of Eminence                 $ 17,824      
Revenues, net               $ 1,159,060 1,136,702 $ 1,105,599    
Gain on sale of Eminence             $ 11,700   11,682      
Gain (loss) on equity method investment               (6,841) $ (1,143)      
Positions eliminated during the period as a percentage           4.00%            
Impairment of Long-Lived Assets to be Disposed of               $ 21,963        
Common stock, shares authorized (in shares) | shares               400,000,000 400,000,000   400,000,000 100,000,000
Declared stock split     4                  
Additional shares | shares   3                    
Number of reporting units | item               5 5 5    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]                   Selling, general and administrative    
Eminence Biotechnology                        
Proceeds from sale of Eminence       $ 17,800                
Goodwill, Impairment Loss                   $ 8,300    
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)                   8,600    
Goodwill, Impairment Loss                   8,300    
Protein Sciences                        
Goodwill attributable to disposal group held for sale           $ 1,400            
Pre-tax restructuring charges                 $ 1,700      
Protein Sciences | Current Assets, Held For Sale                        
Property, plant and equipment attributable to disposal group held for sale               $ 9,800        
Protein Sciences | Eminence Biotechnology                        
Revenues, net             $ 2,000     4,600    
Diagnostics and Genomics                        
Pre-tax restructuring charges                   1,400    
Wilson Wolf Corporation                        
Investment percentage 19.90%                      
Payments to Acquire Investments $ 232,000       $ 25,000              
Forward Contract, Milestone, Multiple for Total Expected Payments               4.4        
Wilson Wolf Corporation | First Part of Forward Contract                        
Forward Contract, Milestone, Annual Revenue Required 92,000                      
Forward Contract, Milestone, Annual EBITDA $ 55,000                      
Wilson Wolf Corporation | Second Part of Forward Contract                        
Forward Contract, Milestone, Annual Revenue Required               $ 226,000        
Forward Contract, Milestone, Annual EBITDA               136,000        
Forward Contract, Additional Investment               $ 1,000,000        
Selling, General and Administrative Expenses | Protein Sciences                        
Asset Impairment Charges           $ 22,000            
QT Holdings Corporation | Protein Sciences                        
Pre-tax restructuring charges                 $ 2,200      
Eminence Biotechnology                        
Inventory Write-down                   900    
Asset Impairment Charges                   $ 900